- Home
- GETY vs VRDN Comparison
GETY vs VRDN Comparison
Compare GETY & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GETY
- VRDN
- Stock Information
- Founded
- GETY 1995
- VRDN 2006
- Country
- GETY United States
- VRDN United States
- Employees
- GETY N/A
- VRDN N/A
- Industry
- GETY Industrial Machinery/Components
- VRDN Medical Specialities
- Sector
- GETY Industrials
- VRDN Health Care
- Exchange
- GETY Nasdaq
- VRDN Nasdaq
- Market Cap
- GETY 1.6B
- VRDN 1.5B
- IPO Year
- GETY N/A
- VRDN N/A
- Fundamental
- Price
- GETY $2.79
- VRDN $19.84
- Analyst Decision
- GETY Strong Buy
- VRDN Strong Buy
- Analyst Count
- GETY 4
- VRDN 10
- Target Price
- GETY $5.61
- VRDN $37.25
- AVG Volume (30 Days)
- GETY 432.7K
- VRDN 1.1M
- Earning Date
- GETY 11-07-2024
- VRDN 11-12-2024
- Dividend Yield
- GETY N/A
- VRDN N/A
- EPS Growth
- GETY N/A
- VRDN N/A
- EPS
- GETY 0.13
- VRDN N/A
- Revenue
- GETY $917,902,000.00
- VRDN $302,000.00
- Revenue This Year
- GETY $3.79
- VRDN N/A
- Revenue Next Year
- GETY $2.37
- VRDN N/A
- P/E Ratio
- GETY $22.16
- VRDN N/A
- Revenue Growth
- GETY N/A
- VRDN N/A
- 52 Week Low
- GETY $2.83
- VRDN $11.40
- 52 Week High
- GETY $5.77
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- GETY 27.13
- VRDN 35.76
- Support Level
- GETY $2.81
- VRDN $19.65
- Resistance Level
- GETY $3.56
- VRDN $20.87
- Average True Range (ATR)
- GETY 0.22
- VRDN 1.33
- MACD
- GETY -0.12
- VRDN -0.50
- Stochastic Oscillator
- GETY 0.59
- VRDN 2.45
About GETY Getty Images Holdings Inc.
Getty Images Holdings Inc is engaged in the core mission of bringing the world's creative and editorial visual content solutions to its customers to engage their audiences. the company has developed market enhancements across e-commerce, content subscriptions, user-generated content, diverse and inclusive content, and proprietary research alongside investment in its technology platform, which includes artificial intelligence and machine learning-driven search functionality and image editing and integrated APIs, to become a trusted industry leader in the visual content. Geographically the company operates in the Americas, Europe, the Middle East, Africa, and Asia-Pacific, out of which a majority of its revenue is generated from the Americas.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.